Specialty Pharmacy

Emflaza treats patients 5 years and older with DMD.

Gene-editing tool shows promise treating genetic diseases.

Manufacturers will present clinical trial results at the upcoming HIV medical meeting.

Glecaprevir/pribrentasvir well-tolerated in patients with HCV genotype 1.

A change from fingolimod to alemtuzumab caused significant disease activity in patients with MS.

Gut antibody imbalance may impact immune response to HIV.

Hypoxic tumor microenvironments influence the fate of disseminated tumor cells.

Top news of the day from across the health care landscape.

For patients with HIV, liver disease is a major cause of morbidity and mortality.

DIR fees continue to generate controversy for pharmacy stakeholders.

The prevalence of cirrhosis has increased by nearly 40% in patients with HCV.

Big data could allow physicians to take action before a patient with cancer needs to visit an emergency hospital.

Aerobic exercise increases hematologic indices in patients with RA.

Macrophages disable protective protein, leaving an open window for HIV infection.

African Americans with breast cancer have a 40% higher death rate than European-Americans.

Top news of the day from across the health care landscape.

Social media can identify behavioral trends and attitudes relevant to the risk of infection with HIV.

The interchangeability designation demonstrates that the efficacy and safety of a biosimilar is equal to the reference product.

With the entrance of more effective and less costly drugs, older treatments will likely decrease.

MicroRNAs could monitor the severity of MS in the future.

Common diabetes drug changes the biology of cancer cells.

Time of day is an important factor in chemotherapy-induced adverse events.

Pro-inflammatory cervicovaginal bacteria increased HIV risk more than 4-fold in women.

Top news of the day from across the health care landscape.

While nephrotoxicity associated with TDF has been well documented, prospective studies in HIV patients have been lacking.

The FDA recently accepted 2 new supplemental biologics license applications from Merck for pembrolizumab (Keytruda) in patients with bladder cancer.

Bristol-Myers Squibb Company recently announced that the FDA approved nivolumab (Opdivo) injection for patients with advanced or metastatic urothelial carcinoma.

Direct and indirect remuneration fees seen to increase costs for Medicare, beneficiaries, pharmacies, and taxpayers.